SR
SR3.F STAAR Surgical Company
- Market cap
- EUR 1.21B
- P/E
- 2,407.0x
- P/B
- 3.19x
- ROE
- 6.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SR3.F undervalued?
Graham numberThe Graham number of STAAR Surgical Company cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
STAAR Surgical Company fundamental analysis
No fundamental analysis for STAAR Surgical Company yet.
STAAR Surgical Company stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health car…
Full company profileSTAAR Surgical Company financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
STAAR Surgical Company annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 82.4M | 90.6M | 124M | 150M | 163M | 230M | 284M | 322M | 314M | 239M | 361M |
| Gross Profit | 58.4M | 64.3M | 91.5M | 112M | 118M | 179M | 223M | 253M | 240M | 182M | 264M |
| Operating Income | -12.7M | -3.63M | 6.60M | 11.9M | 6.77M | 33.3M | 43.8M | 28.1M | -12.6M | -45.9M | 44.0M |
| EBITDA | - | -277K | 9.06M | 15.6M | 9.86M | 37.0M | 48.3M | 33.2M | -5.72M | -37.2M | 55.9M |
| Net Income | -12.1M | -2.14M | 4.97M | 14.0M | 5.91M | 24.5M | 39.0M | 21.3M | -20.2M | -80.4M | 25.1M |
| EPS | - | -0.05 | 0.11 | 0.31 | 0.13 | 0.51 | 0.81 | 0.44 | -0.41 | -1.63 | 0.50 |
| Balance Sheet | |||||||||||
| Total Assets | 65.4M | 67.9M | 167M | 207M | 257M | 346M | 415M | 489M | 510M | 452M | 485M |
| Total Liabilities | 27.5M | 25.0M | 34.9M | 47.0M | 60.2M | 87.2M | 82.7M | 103M | 112M | 107M | 109M |
| Shareholders' Equity | 37.9M | 42.9M | 132M | 160M | 197M | 259M | 332M | 386M | 397M | 344M | 376M |
| Cash & Short-term Investments | 14.0M | 18.5M | 104M | 120M | 152M | 200M | 86.5M | 183M | 144M | 153M | 134M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.05M | 2.85M | 12.8M | 25.8M | 21.0M | 44.0M | 35.7M | 14.6M | 15.7M | -34.2M | 33.7M |
| Capital Expenditure | 3.21M | 1.05M | 2.25M | 10.1M | 8.40M | 13.6M | 18.1M | 18.2M | 23.4M | 5.82M | 2.50M |
| Free Cash Flow | - | 1.81M | 10.5M | 15.6M | 12.5M | 30.3M | 17.6M | -3.59M | -7.67M | -40.1M | 31.3M |
| Ratios | |||||||||||
| ROE | -32.0% | -5.0% | 3.8% | 8.8% | 3.0% | 9.5% | 11.7% | 5.5% | -5.1% | -23.4% | 6.7% |
| ROA | -18.5% | -3.1% | 3.0% | 6.8% | 2.3% | 7.1% | 9.4% | 4.4% | -4.0% | -17.8% | 5.2% |
| Net Profit Margin | -14.7% | -2.4% | 4.0% | 9.4% | 3.6% | 10.6% | 13.7% | 6.6% | -6.4% | -33.6% | 7.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
STAAR Surgical Company dividends
STAAR Surgical Company has not paid dividends in the last 9 fiscal years.
Who owns STAAR Surgical Company
- Insiders 0.85%
- Institutions 99.15%
- Public & others 0.00%
- Shares outstanding 50.2M
- Free float 26.2M
STAAR Surgical Company company profile
- Company name
- STAAR Surgical Company
- Ticker
- SR3.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 921
- Fiscal year end
- December
- Address
- 25510 Commercentre Drive, Lake Forest, CA, United States, 92630
- Phone
- 626 303 7902
- Website
- staar.com
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
STAAR Surgical Company management
10- Mr. Warren FoustCEO, President & Director · born 1976
- Ms. Deborah J. AndrewsExecutive VP & CFO · born 1957
- Dr. Magda Michna Ph.D.Chief Development Officer
- Dr. Ben Park Ph.D.Chief Technology Officer
- Ms. Connie JohnsonDirector of Investor Relations
- Ms. Kathleen Determann J.D.VP, Deputy General Counsel and Chief Compliance & Privacy Officer
- Mr. William W. GoodmenVice President of Global Human Resources · born 1955
- Mr. David BaileyChief Commercial Officer · born 1957
- Dr. Scott D. Barnes M.D.Chief Medical Officer · born 1963
- Mr. Filip De KeersmaeckerChief Supply Chain & Quality Officer